Last updated: 31 July 2023 at 5:40pm EST

Michel Wilde Net Worth



Michel Wilde biography

Dr. Michel De Wilde Ph.D. serves as Independent Director of the Company. Dr. De Wilde has served as a member of our Board since May 2016 and has served as a member of the board of directors of VBI DE since July 2014. Dr. De Wilde was Senior Vice President, Research & Development, at Sanofi Pasteur, the human vaccines division of Sanofi from 2001 until June 2013. In this position, he was responsible for managing approximately 1,500 employees and a broad portfolio of approximately 20 development projects. Prior to joining Sanofi Pasteur in January 2000, Dr. De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) in Rixensart, Belgium. Dr. De Wilde joined the group in 1978 as a research scientist upon formation of a unit focusing on the application of recombinant DNA technology to vaccine development. He subsequently held positions of increasing responsibility and, as Vice President, Research & Development at Sanofi Pasteur, headed a team of approximately 400 specialists, active in all aspects of preclinical vaccine development. Dr. De Wilde was also a Board member at the Infectious Disease Institute December 2014 until December 2019 and is a member of a number of scientific and strategy advisory boards. Dr. De Wilde received his degree in Chemistry from the Free University of Brussels in 1971, followed by a Ph.D. in Biochemistry in 1976. He carried out postdoctoral work at the University of Wisconsin, Madison (U.S.) and the University of Ghent (Belgium). Dr. De Wilde authored over 50 publications during the early part of his career.

What is the salary of Michel Wilde?

As the Independent Director of VBI Vaccines, the total compensation of Michel Wilde at VBI Vaccines is $327,228. There are 10 executives at VBI Vaccines getting paid more, with Jeffrey Baxter having the highest compensation of $1,379,630.



How old is Michel Wilde?

Michel Wilde is 70, he's been the Independent Director of VBI Vaccines since 2016. There are no older and 19 younger executives at VBI Vaccines.

What's Michel Wilde's mailing address?

Michel's mailing address filed with the SEC is C/O VBI VACCINES INC.,, 160 SECOND STREET, FLOOR 3, CAMBRIDGE, MA, 02142.

Insiders trading at VBI Vaccines

Over the last 8 years, insiders at VBI Vaccines have traded over $18,633,012 worth of VBI Vaccines stock and bought 55,142,222 units worth $66,770,591 . The most active insiders traders include Advisors Llcperceptive Life..., Tomer Kariv, and Steven D Rubin. On average, VBI Vaccines executives and independent directors trade stock every 62 days with the average trade being worth of $130,457. The most recent stock trade was executed by Steven Gillis on 10 July 2023, trading 609,090 units of VBIV stock currently worth $1,004,999.



What does VBI Vaccines do?

vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.



What does VBI Vaccines's logo look like?

VBI Vaccines Inc. logo

VBI Vaccines executives and stock owners

VBI Vaccines executives and other stock owners filed with the SEC include: